Phagenesis
Manchester
About Phagenesis
Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "cortical remapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $71.4M
- Funding stage: M&A
- Last round: Series D (Mar 2024)
- Website: phagenesis.com
- Phone: +44 161 820 4525
Industries & Categories
Biotechnology, Health Care, Medical, Neuroscience
Social Profiles
Canonical: https://fsome.com/organization/phagenesis-125505 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.